Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, has emerged as an effective therapeutic agent for the management of treatment-resistant depression. Repeated treatments with ...

B-2D, a brain receptor targeted by ketamine. Using cryo-EM, they visualize how ketamine binds to the receptor, controlling its ion channel activity.

Introduction Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of ...

Scientists think ketamine relieves depression and anxiety by altering GluN1-2B-2D’s movements, but the effects can vary ...

Ketamine has received a Hollywood makeover. It used to be known as a rave drug (street name special K) and cat anesthetic.

New research sheds light on how ketamine affects the brain by targeting a specific NMDA receptor subtype, GluN1-2B-2D.

An Anesthetic Drug That Can Also Be Abused ...

Now ketamine, a glutamatergic NMDA receptor antagonist, may provide a mechanism that could link these pathways. Figure 1: A schematic of how ketamine may lead to an overall excitation in the cortex.

MIT neuroscientists have made a breakthrough in treating fragile X syndrome by leveraging a novel neurotransmitter signaling ...

One main class of these drugs, which includes propofol and the ether-derivative sevoflurane, work primarily by increasing the activity of inhibitory GABAA receptors, while a second class that includes ...

IntroductionMajor depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing ...